About
Harout Semerjian is a biopharma executive. As of June 16, 2026, Geron’s official leadership materials list him as President and Chief Executive Officer and a member of the board, with service beginning in August 2025. Previously he was CEO of GlycoMimetics from August 2021 until February 2025, briefly CEO of Immunomedics in April-May 2020, and earlier held senior commercial leadership roles at Ipsen and Novartis.
Areas of interest
biotechoncologyhematologyrare diseasespharmaceuticalscommercializationhealthcare